GSK's Big Reveal: An R&D Overhaul Poised To Yield Long-Term Cultural Change
With few near-term catalysts, GSK's R&D strategy may leave some investors underwhelmed, but President-R&D Hal Barron is focused on making deep cultural and scientific changes at the big pharma. He laid out his initial turnaround plan July 25.
